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Abstract  
 
Background: In May 2012, the United States Preventive Services Task Force recommended against PSA-based 
screening in men of all ages, regardless of race or family history.   However, though risk of harms outweighs 
potential benefits in men in the general population, men at higher risk of dying from prostate cancer may have a 
larger mortality benefit.  Although previous reviews have demonstrated that family history of prostate cancer in a 
first-degree relative is a risk factor for overall prostate cancer, this may not correspond to a higher risk of death.  In 
this review we assess family history as a risk factor for aggressive prostate cancer to determine if men with family 
history have a potentially larger mortality benefit than average risk men.   
Purpose: To determine the relative and absolute risk of aggressive prostate cancer in men with at least one affected 
first-degree relative 
Data Sources: MEDLINE and Embase (search dates 1992 to June 2012), recent systematic reviews, reference lists 
of retrieved articles and suggestions from experts. 
Study Selection: English-language, randomized, controlled trials, cohort studies, case-control studies and cross-
sectional studies meeting eligibility criteria 
Data Extraction: All studies were reviewed, abstracted and rated for quality using the STROBE criteria and 
supplemented with guidelines provided by Deets et al.   
Data Synthesis: Three fair quality cohort studies, one fair quality and six poor quality case-control studies and one 
fair quality cross-sectional study demonstrated mixed results of difference of risk magnitude for aggressive prostate 
cancer in men with family history of prostate cancer in a first-degree relative compared to men without family 
history.  In cohort studies reporting increased relative risk, we calculated absolute risk and attributable risk to be 
small.   
Limitations: There is limited evidence from good quality studies addressing aggressive prostate cancer risk in men 
with family history.  Use of surrogates, inability to assess harms and variations among study populations by region, 
age, co-variates and prior screening rates limits generalizability.   
Conclusion: Evidence is insufficient to suggest an increase in relative or absolute risk of aggressive prostate cancer 
in men with an affected relative compared to men in the general population without determining family history in 
greater detail (age of diagnosis, cause of death, intent of treatment, etc.).   
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“Now, I probably won't be entering a discussion about prostate cancer screening unless my 
patient has a family history of prostate cancer or he expresses concern,” said general internist 
Christine Laine, MD, MPH, editor in chief of Annals of Internal Medicine.
1
 
 
Focused question 
What is the relative and absolute risk of aggressive prostate cancer in men aged 
40-70 years who have a family history of prostate cancer in at least one first-
degree relative compared to men without such family history?   
Introduction 
Statement of Purpose 
On March 22, 2012, the United States Preventive Services Task Force (USPSTF) 
recommended against prostate specific antigen (PSA)-based screening for prostate cancer 
in all men, regardless of age, race or family history.
2
 These recommendations were, in a 
large part, based on results from two large randomized trials which showed only a small
3, 4
 
or no mortality benefit
5, 6
 from PSA-based screening.  Risk of harms outweighs potential 
benefit in average risk men, “high-risk” men (men with a family history and African 
American men), may have larger mortality benefit.   Although randomized trials are 
needed to evaluate PSA-based screening in “high-risk” groups, determining the magnitude 
of risk for men with family history compared to men in the general population is a 
prerequisite.  Previous reviews have documented family history as a risk factor for overall 
prostate cancer;
7-9
 however, it is important to distinguish aggressive – clinically 
significant – from indolent – clinically insignificant – prostate cancer.  We will use the 
term overall prostate cancer to refer to the sum of indolent and aggressive prostate cancer. 
We will define aggressive prostate cancer below (see Defining Aggressive Disease).  The 
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purpose of this review is to examine and accurately report
10
 the level of evidence on risk 
of aggressive prostate cancer in men with a family history compared to those without.   
Background  
Prostate Cancer in the “PSA-era” 
The incidence rates of prostate cancer in the United States increased dramatically 
as PSA-based screening became clinically accepted, peaking at nearly 250 cases per 
100,000 in the early 1990’s.11 However, despite its widespread use, the role of the PSA in 
screening for prostate cancer has become and will likely continue to be controversial. In 
2009, the publication of two large, randomized controlled trials, the European 
Randomized Study of Screening for Prostate Cancer (ERSPC) and the United States 
Prostate, Lung, Colorectal and Ovarian (US PLCO) studies showed small
3
 and no
5
 
survival benefit, respectively. These trials continued to yield conflicting results with 
continued patient follow-up.
4, 6
 In May 2012, the United States Preventive Services Task 
Force recommended against PSA-based screening with the finding that the risk of harms 
outweighed the benefits.
2, 12
 Based on data from the ERSPC, an estimated 1055 men need 
to be screened to prevent 1 death from prostate cancer.
3
  However, the number needed to 
screen may be smaller for “high-risk” men, such as those with a positive family history.   
Scope of Review 
 In this review, we examined the evidence on risk of aggressive – clinically 
significant – prostate cancer in men with a family history.  This review is meant to inform 
practitioners and allow for better more complete discussion with their patients with 
affected relatives.  It is also intended assist in assisting the need for randomized trials 
evaluating screening in this group of men.  Given the current uncertainty of screening in 
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these men, a review of the evidence specifically regarding aggressive disease is imperative 
for health care providers in promoting informed discussions with patients regarding 
derivation of benefit or avoidance of harm of screening and treatment. Furthermore, we 
also hope that by characterizing the risk magnitude in these men, we may gain insight into 
the potential benefit of screening in this group and determine if it is greater than for men 
in the general population. 
Recommendations of Other Associations 
 The American Urological Association (AUA), American Association of Clinical 
Urology and other individual experts in the field have been critical of the new guidelines, 
citing concerns about study quality and emphasizing the need for more complete 
understanding of the clinical contexts and consequences.
13-17
 With regards to men with 
positive family history, both the AUA and American Cancer Society (ACS) recommend 
offering screening to men at age 40 and prior to age 50, respectively.
18, 19
 The American 
Academy of Family Physicians (AAFP) and the United States Preventive Services Task 
Force recommend against screening for men of all ages, regardless of race or family 
history.
2, 20
  The disagreement among medical professional societies will contribute to the 
challenge patients and their providers face in the context of a shifting preventive care 
paradigm.   
Epidemiology 
Prostate cancer remains the most commonly diagnosed solid tumor and the second 
leading cause of cancer-related death in American men.
21
 In the “PSA-era” the risk of 
being diagnosed with prostate cancer has increased, however the risk of dying from 
prostate cancer has remained relatively constant.
22
 A man born today has a 16% chance of 
6 
 
being diagnosed with prostate cancer and a 3% chance of dying from the disease.
23
 In 
2011, an estimated 240,890 men were diagnosed with prostate cancer and 33,720 men 
died from the disease.
23
  Although these estimates do not distinguish aggressive from 
overall disease, both prostate cancer diagnosis and mortality clearly represent a 
considerable burden for the United States population. The epidemiology of aggressive 
prostate cancer is unclear.  The prevalence of overall prostate cancer in men with an 
affected relative is estimated at 2- to 4- fold greater than the general population.
24
  The 
prevalence of aggressive prostate cancer in men with a family history is the subject of our 
review.  
Prostate Cancer Risk Factors 
 There are several risk factors for overall prostate cancer that are supported by a 
strong body of evidence, while for others the evidence is less robust.  We discuss all 
known risk factors for prostate cancer below as the implications of cumulative risk may be 
important clinically.  Note that we will discuss risk of aggressive disease when known, 
however for many factors the association is unclear. 
Age 
Age has a stronger relationship with prostate cancer than perhaps any other 
malignancy. Prostate cancer is exceedingly rare prior to age 40 and occurs most frequently 
in individuals over 60 years of age.
25
 Estimated incidence rates of prostate cancer in men 
40-49 is 50-100 per 100,000 compared to 600-800 per 100,000 in men aged 60-69.
22
 
While these incidence rates apply to those prostate cancers diagnosed clinically (by PSA-
based screening and or with symptoms), the prevalence of occult prostate cancer is much 
greater.  Autopsy studies are highly variable but have shown that that up to 43% of men 
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aged 41-50, 46% aged 51-60, 70% aged 61-70, and 83% aged 71-80 have histological 
evidence of malignancy with no clinical evidence of disease.
26
 
Ethnicity 
Ethnicity is also considered to increase risk of prostate cancer. African American 
men are 1.6 times as likely to develop the disease than Caucasian, Hispanic and Asian 
men (incidence rates of approximately 226 and 145 cases per 100,000 person-years for 
African American men and Caucasian men, respectively) and are 2.3 times more likely to 
die from prostate cancer.
22
 Additionally, African Americans are more likely to be 
diagnosed with more aggressive disease at an earlier age compared to Caucasian men.
27, 28
  
However, the role of disparity in healthcare access and trust of healthcare professionals 
may confound the differences in incidence and mortality.
29
 African American men may 
also be more likely to be diagnosed due to –on average – higher measured PSA levels 
compared to Caucasian men and when stratified by age, access, stage at diagnosis, some 
studies show ethnicity may not independently have implications for outcomes.
30
 
Family History 
 Family history of prostate cancer in a first or second degree relative is considered 
to increase risk of overall prostate cancer.  The association with aggressive prostate cancer 
is unclear and thus the reason for this review.  With regard to risk of overall prostate 
cancer, estimates of relative risk compared to men without family history vary as widely 
as 1.4 to 17.8 in first-degree relatives.
9
 We will address family history as a risk factor for 
overall prostate cancer below in our discussion of previous systematic reviews and meta-
analyses.  Specific genotypes (BRCA 1 and 2 mutations, HOXB13) are discussed in the 
Genetics of Prostate Cancer section.  
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Other Factors  
 Androgens have also been shown to increase risk for overall prostate cancer.  Use 
of 5-alpha-reductase inhibitor, finasteride, was shown to decrease risk of cancer in the 
Prostate Cancer Prevention Trial (PCPT).
31
 Many other factors have been reported in the 
literature to increase prostate cancer risk. These risk factors include animal fat, vegetable 
matter, soy, alcohol, coffee, obesity, insulin and insulin-like growth factor, physical 
activity, vasectomy, ejaculatory frequency, ultraviolet light exposure, diagnostic 
radiologic procedure, external beam radiotherapy, prostatitis with Trichomonas, XMRV 
virus, exposures such as Agent Orange, Chlordecone, medications such as NSAIDs and 
statins, and vitamins and minerals including vitamin E, folic acid, selenium, zinc, calcium 
and vitamin D.
32
  The quality and clinical contribution of these studies investigating these 
associations is beyond the scope of this review.  
Genetics of Prostate Cancer 
Numerous studies report risk of prostate cancer is strongly affected by family 
history, particularly early onset disease.  Several studies, including family studies and 
genome-wide association studies have suggested that prostate cancer has a strong genetic 
component, an estimated 5-10% of prostate cancer cases are believed to be due to “high-
risk” genetic factors and/or susceptibility genes.33  Generally, it is believed that there are 
three forms of prostate cancer.  Sporadic prostate cancer occurs randomly in the general 
population, familial cancer occurs in unpredictable clusters of disease within multiple 
families and hereditary prostate cancer occurs in predictable clusters within individual 
families; among hereditary cancer, some have been shown to occur prior to age 50 and are 
associated with rapidly aggressive disease.
34
 Classically, hereditary prostate cancer is 
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considered to be passed on by autosomal dominance transmission and represents as many 
as 43% of prostate cancers diagnosed before age 55, but only 9% of prostate cancers in 
men overall.
35
   
In a recent review of 8 prostate cancer large linkage studies that evaluated 4,600 
cases of prostate cancer from 1,293 kindreds,  a lack of consistency was found among 
genetic models; Easton et al. concluded that prostate cancer is genetically complex and 
would require large family sets to draw reliable linkages.
36
 Another review found that 
several genomic regions are linked to high-grade tumors, but the prevalence and 
interaction with diet and environment are unknown.
37
 However, certain predispositions for 
overall prostate cancer have recently been evaluated with consistent findings.  Cohort 
studies show HOXB13, BRCA1 and BRCA2 mutations place individuals at higher risk.
38, 
39
  A population-based study of prostate cancer cohort in Seattle reported 22 single 
nucleotide polymorphisms (SNPs) found to be significantly associated with prostate 
cancer-specific mortality, but these results await validation and replicaton.
40
 
In summary, although the genetics of prostate cancer is a rapidly developing field, 
much remains unknown.  While BRCA mutations may have implications for overall 
prostate cancer, few studies consistently show specific genotypic predispositions for 
aggressive disease.  Furthermore, if genetic contexts that predispose to aggressive prostate 
cancers can be validated, the prevalence in the general population is unclear.  Finally, the 
benefit of PSA-based screening in these populations, if they exist and are reliably 
detectable, is unclear.   
Detection to Diagnosis  
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 Since the PSA-based screening became widespread, many prostate cancers are 
detected asymptomatically.  Other modes of detection include digital rectal 
examination(DRE) or with symptoms.  On DRE, prostate cancers are asymmetric areas of 
induration or nodules detected by manual examination.  Symptoms suggestive of prostate 
cancer include new onset urinary urgency, nocturia, frequency, hesitancy, or new onset 
erectile dysfunction.  Bone pain may be a presenting symptom in a small percentage of 
men with metastatic disease.  Any of the above presentations warrants a prostate biopsy.  
Prostatic biopsy varies with regard to procedure; anatomic approaches include transrectal, 
transperineal and transurethral resection.  Though it has many risks, prostate biopsy is 
considered to be a minimally invasive procedure performed in the office setting.  
Prophylactic antibiotics are recommended prior to biopsy to lower incidence of post-
biopsy bacteruira.
41
  Local anesthesia can be given to reduce patient discomfort.  Most 
often in current practice, an extended core (5-7 specimens from each side of the gland or 
occasionally up to 18 cores) or saturation biopsy (up to 24 core samples) are performed to 
observe neoplastic cells within the gland.   
PSA Test Characteristics  
 As a screening test for early detection of prostate cancer, the PSA has many 
limitations.  The sensitivity of the PSA test for high-grade disease is estimated at 51% 
using a cut-off of 4.0 ng/mL; the test also has poor positive predictive value as less than 
one in three men with an elevated PSA will have any grade of prostate cancer on biopsy.
42
 
Although the test has a specificity of 90% at 4.0 ng/mL,
18
  the PSA has a false-positive 
rate of approximately 80% at cut-offs between 2.5 to 4.0 ng/mL.
4
   In the PLCO trial, men 
in the screening group had a 12.9% chance of receiving at least 1 false-positive test after 
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undergoing 4 PSA tests and a 5.5% risk of having at least 1 biopsy due to a false-
positive.
2, 6
  Although increasing and decreasing PSA cut-offs would improve specificity 
and sensitivity, respectively, there is no PSA level at which a man can know for certain he 
is without a life-threatening prostate cancer.
43
 
Efforts to improve the ability of the test to detect early disease have included use 
of PSA velocity, density and free-to-total PSA ratios.
44-46
 Use of PSA velocity, while 
predictive of prostate cancer, does not appear to improve detection of high-grade disease 
and tends to increase biopsy rates.
47
  PSA density may improve sensitivity and decrease 
unnecessary biopsies, but is limited in clinical applicability as it requires prostatic volume 
measurement with ultrasound or MRI.
45
  Similarly, free PSA is only considered clinically 
useful at extreme values and is not standard practice.
46
  Recently, urinary biomarkers 
including PCA3, alpha-methylacyl-CoA racemase, the TMPRSS2-ERG fusion gene and 
microseminoprotein-beta have been proposed for early detection of prostate cancer,
48
 
however to our knowledge these tools await validation and have not yet been evaluated in 
randomized trials.  
Outcomes of Screen-detected and Overall Prostate Cancer 
 The USPSTF recommendation statement described three categories of men with 
screen-detected prostate cancers: those who will die despite early detection and 
intervention, those who would not have died regardless of screening, and those in whom 
early detection and intervention may have a mortality benefit.
2
 In average risk men, an 
estimated 5 in 1000 die of prostate cancer without screening compared to 4-5 in 1000 with 
screening.
2, 4
 The fact that screening has been shown to have only a small potential benefit 
is likely attributable to several factors, including limited utility of PSA-based screening 
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and advances in treatment.  Additionally, it may be that particularly aggressive tumors are 
largely undifferentiated and therefore do not produce PSA.  An estimated 25% of men 
with PSA below 4 have Gleason scores of 7 or more, 12.5% of men have high-grade 
disease with PSA of 0.5 ng/mL or less.
49
 However, these estimates may not be applicable 
for men at higher risk for overall or aggressive prostate cancer. 
TNM Stage and Gleason Score 
 Prostate cancer is staged with the TNM system.  Of some importance to our 
review, the TNM system underwent changes in 2002 and 2010.  The most recent change 
incorporated Gleason score as the standardized histopathology grading system (previous 
systems did not specify the system to be used for grading histopathology).  The Gleason 
score has also experienced an “upward migration” over the study period, as the percentage 
of higher grade Gleason has increased over time which is known as the Will Rogers 
phenomenon.
50
 
Defining Aggressive Disease 
 In men with localized disease, the TNM Stage, Gleason score and PSA level prior 
to treatment are the most important prognosticators, predicting both probability of distant 
disease and survival.  Additionally, these measures also guide therapeutic approach and 
treatment modality.  For local disease, radical prostatectomy and external beam radiation 
therapy are both employed in combination or as single modalities, with or without 
hormonal therapy.  Advanced (nodal positive) disease requires more intensive regimens 
and metastatic disease is treated with palliative hormonal and radiotherapy.  A more 
detailed description of treatment options for local and advanced prostate cancer is beyond 
the scope of this review but can be found in the NCCN guidelines.
51
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The TNM Stage refers to tumor size, nodal status and presence of distant 
metastases.  While a T1b tumor has a 5-year survival of 85%, tumors greater than T2 have 
5-year survivals of less than 66%.
52
  The Gleason score reflects the degree of 
histopathology and predicts the likelihood of organ confined disease with implications for 
survival.  A tumor’s overall Gleason score is a composite of the two most predominant 
growth and differentiation grades – where grade 1 is the most and grade 5 is the least 
differentiated – present within a tissue sample.53  While a Gleason score of less than 7 
correlates with a 10-year survival rate of 98.4%, a Gleason score of 8 or greater 
corresponds to a 10-year survival rate of less than seventy-percent.
51, 54
 Similarly, PSA 
levels at the time of diagnosis correlate with the aggressiveness of disease and mortality.  
For a PSA of 10 or less, the 5-year survival is approximately 81% compared to 51 and 
31% at PSA values 20-30 and greater than 30 ng/mL, respectfully.
52
  
The 2010 TNM Anatomic Stage/Prognostic Groups are provided in Table 1.  As 
shown in the table, TNM Stage and Gleason score both have “thresholds” at which 
Anatomic Stage and thus prognosis, change significantly.  For the purposes of our review, 
we required an aggressive cancer to have at least 1 of these “advanced” characteristics.  
Based on TNM 2010 Anatomic Stage, aggressive disease had at least one of the following 
tumor characteristics: TNM Stage T3a or greater, Gleason Score of 7 or greater, or 
pretreatment PSA of 20 ng/mL or more.
55-57
    
Table 1. RTOG prognostic model for disease-specific survival in early stage prostate cancer
58
 
 5 year (%) 10 year (%) 15 year (%) 
Group 1 96 86 73 
Group 2  94 75 61 
Group 3 83 62 39 
Group 4 64 34 27 
Group 1 – Gleason score 2-6, T1-2, Nx 
Group 2 – Gleason score 206, T3, Nx, or Gleason score 206, N+, or Gleason score 7, T1-2, Nx 
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Group 3 – Gleason score 7, T3Nx, or Gleason score 7, N+; or Gleason score 8-10, t1-2 Nx 
Group 4 – Gleason score 8-10, T3Nx; or Gleason score 8-10, N+ 
 
Burden of Suffering 
 Population-based studies estimate the prevalence of family history of prostate cancer to 
be approximately 5-7%.
59, 60
 Men with a positive family history have increased risk perception 
compared to men without a family history which can lead to depression and worry that affects 
daily life.
61
 Population-based studies show that while 60% of men with first-degree relatives 
worry little or not at all about prostate cancer, the remaining 40% worry to an extreme degree.
62
 
A review on PSA-based screening “uptake” in men with family history of prostate cancer 
reported 50-95% of men received PSA-based screening with variations by socioeconomic status 
and race.
63
 
Harms of PSA-based Screening in Average Risk Men 
 Prostate biopsy is usually uncomplicated and well-tolerated, but harms must be 
considered.  Harms of prostatic biopsy include anxiety, infection, pain, bleeding, urinary 
obstruction and tumor seeding, although this is unusual.  Risk of infection is lowered with 
single dose of prophylactic antibiotic therapy, but has contributed to overuse of 
fluoroquinolone antibiotics.
41
  Men on anticoagulant therapy are recommended to 
temporarily stop the medication prior to biopsy.  Most bleeding is self-limited and requires 
no intervention.  Hematuria and/or hematospermia occur in as many as 50% of men and in 
23%, it lasts more than 3 days.
64
 Retrospective studies show up to 3.5% of men develop 
post-biopsy fever, but less than 1% required hospitalization.
64
  Most men with screen-
detected cancers will elect to have treatment.
65
 Harms associated with treatment depend on 
the modalities employed.  Up to 0.5% of men will die within 30 days of radical 
prostatectomy (similar to rates of any major operation), 3-7% will have serious 
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complications and 20-30% of men will experience erectile dysfunction, urinary 
incontinence or both after 10 years; radiation therapy can also increase risk of erectile, 
bowel and bladder dysfuntion.
66
  
Potential Harms in Men with Family History 
 If family history is associated with aggressive disease, it could be the harms of 
screening become outweighed by the benefits of early detection and intervention.  
However, if a review of the literature reveals no or little increase in risk of aggressive 
prostate cancer, men with a family history could represent a subgroup at high risk for 
harms of screening, diagnosis and treatment.   
Previous Systematic Reviews and Meta-Analyses 
 As mentioned above previous reviews have identified risk of overall prostate 
cancer in men with a family history.  In 2003, Johns and Houlston identified 13 case-
control and cohort studies assessing risk for categories of family history (father, son); 
meta-analysis showed pooled relative risk of 2.5 (confidence interval 2.2 to 2.8) of overall 
prostate cancer in first-degree relatives.
67
 Also in 2003, Zeegers et al. published a meta-
analysis on 33 studies and found a “recurrence risk ratio” of 2.53 (2.24-2.85) of overall 
prostate cancer for first-degree family members, more pronounced in men with an affected 
brother than father.  Bruner et al. also published a meta-analysis of 24 studies in 2003, 
reporting a relative risk 2.22 (2.06-2.40) for first-degree relatives for overall prostate 
cancer.
9
 In 2010, Madersbacher et al.
68
  and Robool et al.
69
 both conducted informal 
systematic reviews reporting strong evidence of an association between family history of 
prostate cancer and increased risk of developing the disease.  
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One concern with previous reviews is the risk of selection bias. Logically, men 
with a positive family history are more likely to be aware of the disease and therefore 
more likely to be screened.  Because indolent prostate cancer is present in such a large 
percentage of the population and PSA is an inaccurate test, this group of men may, 
therefore, be more likely to be overdiagnosed with a prostate cancer that may have never 
caused symptoms during their lifetime.  In this review we limit our report to risk of 
aggressive, clinically significant disease in men with a family history of prostate cancer in 
at least one first-degree relative.  
Summary  
 Age, race and family history are considered to be the three most valuable risk 
factors for prostate cancer. PSA-based screening is the central modality for early detection 
and intervention of prostate cancer.  In May 2012, the USPSTF found that the risk of 
harms outweighed potential benefits of PSA-based screening for average risk men, 
however this may not be true for “high-risk” groups.  The potential for a mortality benefit 
in high risk groups depends in part on family history as a risk factor for aggressive 
disease.  The purpose of this report is to review the literature and examine risk of 
aggressive disease in men with a family history of prostate cancer in a first-degree relative 
compared to men in general population.   
Key Question:  
This review aims to address the following questions:  
1. What is the relative risk of aggressive prostate cancer in men with a positive 
family history?  
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2. If there is an increased relative risk, what is the absolute risk of aggressive prostate 
cancer in men with a positive family history?   
Methods:  
Literature Search 
We developed a search strategy to address our question with the assistance of a 
research librarian.  We conducted a systematic search of MEDLINE and Embase.  Both 
MEDLINE and Embase were accessible through the University of North Carolina at 
Chapel Hill’s Health Science Library.  See Appendix for detailed description of search 
strategy.   
Study Eligibility:  
           To be included in the review, studies must have identified the study population, 
intervention, comparator group, outcomes, time allotted for outcome development and be 
within the time range specified for published literature and have described the study 
design.  Figure 1 presents the eligibility criteria with the PECOTTS framework.   
Figure 1: Focused Question in PECOTTS framework 
Population:   Men aged 40-70 who have had at 
least one first-degree relative 
diagnosed with prostate cancer 
Exposure Reliable establishment of family 
history  
Comparator US men aged 40-70 without 
family history of prostate cancer in 
a first-degree relative 
Outcome Diagnosis of aggressive prostate 
cancer as defined by one of the 
following: 
1. Gleason score ≥7 
2. TNM stage T3 or greater 
3. Pretreatment PSA ≥ 20  
4. Prostate Cancer Death 
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Time allotted for outcome 40 years 
Time period for literature search 1992 - 2012 
Study Designs Reviewed Randomized, cohort, case-control 
studies, cross-sectional 
 
Inclusion and Exclusion Criteria 
 Studies were assessed with inclusion and exclusion criteria described in the 
PECOTTS framework, described briefly in Figure 1.  The following is a detailed 
description of the inclusion and exclusion criteria using the PECOTTS framework.   
Population 
 We defined for population a priori as all men aged 40 to 70 living in the United 
States.  These ages were chosen because guidelines and best practice policies from 
nationally recognized organizations including the AUA, ACS and USPSTF have 
recommended or currently support screening for average and or high-risk men in this 30 
year period.   The magnitude of risk in this population has clinical implications.  Although 
the benefit of screening average risk men is outweighed by risk of harms, men with a 
family history of prostate cancer have a potentially different ratio of benefits and harms.  
A finding of large magnitude would underscore the importance for randomized trials 
evaluating PSA-based screening in men with affected relatives.  Conversely, if the 
magnitude of risk was found to be equivalent or only marginally larger in this population 
compared to the average population, it may be reasonable to apply the results of the 
ERSPC and PLCO trials to men with positive family history as well.  Furthermore, if men 
in this population an increased perception of risk despite having no clinically meaningful 
increase in risk, men with affected relatives may be at high-risk for screening-based 
harms.   
19 
 
Disclosure of Changes – Population  
 As we conducted our search, two minor changes were discussed and agreed upon 
for the population criteria.  Although we had hoped to include only men aged 40-70 years, 
we observed several studies which would have been included if not for the age distribution 
of the study population.  We felt that it would be unreasonable to exclude a study if the 
age range did not align itself exactly with our predetermined criteria.  Furthermore, many 
clinicians would argue that life expectancy should play a role in determining the benefits 
and harms of an intervention, thus in some men over 70 it could be reasonable to employ a 
particular intervention after considering context.  The second alteration to our population 
criteria was nationality of study participants.  We determined that it was not reasonable to 
exclude a study solely because the population of participants did not consist of United 
States men.  In fact, when reviewing benefits and harms of PSA-based screening in men, 
the USPSTF made no such exclusion, including both randomized trials from both Europe
3, 
4
 and the United States.
5, 6
  However, we did consider nationality of study population in 
assessment of external validity which was determined in part by degree to which the study 
findings were applicable to men with affected relatives in the US population. 
Exposure and Comparator 
 The exposure required for inclusion was documentation of a family history of 
prostate cancer in at least one first-degree relative by medical records, registry, self-
administered or interview-administered questionnaire.  Included studies were also required 
to demonstrate an adequate comparator group that closely resembled cases or those 
exposed but had no documented first-degree relatives previously diagnosed with prostate 
cancer.  We included studies that stratified estimations of risk by the number of first-
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degree relatives, although we list these findings only in the appendix as this is beyond the 
scope of this current review. 
Outcome 
 Included studies were required document aggressive prostate cancer.  As 
determined by an abbreviated panel and discussed in the Introduction, determination of 
aggressive prostate cancer required the study to report any of the following characteristics: 
pathologic or clinical TNM Stage, Gleason pathologic grade, pre-diagnosis PSA or 
prostate cancer death.  Aggressive disease was defined as Gleason score greater than or 
equal to 7, clinical or pathologic TNM Stage of T3a or greater, pretreatment PSA of 20 
ng/mL or more or death attributed to prostate cancer.  The definition of aggressive disease 
is modified from the 2010 TNM Staging System and corresponds to higher mortality than 
non-aggressive disease.
70-72
 
Absolute and Relative Risk 
Though clearly valuable in determining relative risk, cross-sectional and case-
control designs do have limitations, one of which being the inability to provide an 
absolute risk.  Relative risks, also known as risk ratios, indicate the change in risk – or 
probability of observing an event or outcome – associated with an intervention or patient 
“risk factor,” compared to a control.  Relative risks provide a measure of overall 
probability of an outcome or event occurring, but do not provide insight into the 
significance of an intervention or patient factor in absolute terms.  For example, though a 
relative risk for a particular patient characteristic could be very large, if the absolute risk 
associated with that characteristic is small, the magnitude of the change in risk, at least 
clinically, may be insignificant.  For this reason, the magnitude of the increase in absolute 
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risk provides a more complete understanding of family history as a clinically meaningful 
risk factor.   
Without an understanding of the absolute risk of positive family history, it could 
be harmful to weight this risk factor heavily when defining groups of men most likely to 
benefit and least likely to be harmed by screening with the PSA.  Therefore, we will report 
or calculate absolute risk and attributable risk from all cohort studies that find a significant 
increase in risk of aggressive cancer in men with compared to those without affected 
relatives.  If a study does not report a significant difference between men with and without 
a family history, there will be no difference in absolute risk.   
Time Period in Literature 
 The time period over which the literature was included was between the year 1992 
to the present time.  This range was chosen because of the considerable prevalence in 
clinical practice of using PSA as a screening tool for prostate cancer.  As referenced 
above, the introduction of the PSA as a screening tool has had a large effect on the 
frequency and stage at which prostate cancer is diagnosed.   
Time Period Allotted for Outcome  
The time allotted for the outcome to become detectable was forty years of age as the 
disease –regardless of any combination of risk factors – is considered to be very 
infrequent in men younger than 40.
22
  As described above, we had initially set a limit of 70 
years for the outcome to occur, however we determined that setting such a limit was not 
clinically justifiable and additionally would have limited our search yield without 
sufficient reason.   
Study Design 
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 We limited the review to randomized-controlled trials, cohort studies, case-control 
and cross-sectional studies.  Only randomized studies and cohort studies would allow for 
evaluation of absolute risk.  Absolute risk was only calculated if a difference in relative 
risk was found.  Case-control studies reporting odds for aggressive disease (or providing 
necessary data for calculation) approximated risk ratios as aggressive prostate cancer is a 
rare event in the general population.  However, odds could overestimate the relative risk if 
evidence shows that aggressive prostate cancer is not a rare event in men with affected 
relatives, but considering that only 3% of men die from prostate cancer, this was unlikely 
to be observed.  Overestimation of risk, if it was found to exist, would be accounted for in 
interpretation of results and have implication for internal validity. Cross-sectional studies 
were included as family history can be considered – to a certain degree – to be a constant 
risk factor.  If family history is considered a constant risk factor (genetic predisposition), a 
cross-sectional study will approximate a longitudinal study.  Meta-analyses and systematic 
reviews were identified and examined for additional references, but were not themselves 
included in the analysis as doing so would have introduced redundancy and either dilution 
or magnification of the magnitude of risk.  
Use of Observational Studies 
 Although we included randomized trials in our search strategy (see above), to our 
knowledge, there have been no randomized controlled trials examining aggressive prostate 
cancer and family history.  Such studies would most likely be designed to compare PSA-
based screening to no screening with outcomes of aggressive cancer and mortality.  As 
mentioned previously, our interest is not in determining the utility of screening in this 
population as it is beyond the scope of this review.  Rather, we aim to understand the 
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magnitude of risk that men with a family history face of dying from prostate cancer using 
aggressive disease as a surrogate.  For this purpose, cohort, case-control and cross-
sectional studies are valuable.   
Additional Criteria (a priori) 
 Studies were excluded if they provided incidence rates or relative risks of 
particular polymorphisms (e.g. a particular SNP, risk loci on chromosome 8q24 or 
mutated receptor) without also addressing risk of overall prostate cancer and aggressive 
prostate cancer.  The degree of association and corresponding risk for aggressive prostate 
cancer and a specific genotype—phenotype is beyond the scope of this review.  However, 
studies could still be included if they provided enough information for the reviewer to 
determine risk of aggressive prostate cancer in those with and without a family history of 
the disease.    
Process of Study Selection 
 We examined the results from the searches described above by abstract, noting 
study design, exposure and outcome assessment, and publication date.  A second reader 
did this as well, independently.  In an effort to include as many studies as possible for full-
text review, exclusions were only made at this stage if it was clear that a study would not 
answer or was not relevant to our key question.  The majority of these excluded studies 
fell into one of three categories: studies of familial cancers other than prostate cancer, 
studies of risk factors for prostate cancer other than family history and studies focusing on 
specific polymorphisms or genotypic permutations.  While certainly valuable to 
understanding the key question, results of this latter category were filed and examined in 
the later sections (see Genetics of Prostate Cancer, Discussion), but did not contribute to 
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the evaluation of risk of family history in the general population.   At the time of 
independent review, if either of the reviewers determined that an abstract did not clearly 
fail to meet eligibility criteria, the entire body of the article was examined.  If the 
reviewers failed to agree on the ability of a study to meet criteria, the entire article was 
reviewed independently by a senior third reviewer.   
Assessment of Quality  
Process of Assessment 
The quality of the studies included in the review was assessed by criteria 
developed by the USPSTF for randomized trials and with Strengthening the Reporting of 
Observational Studies in Epidemiology Statement (STROBE)
73
 and criteria outlined by 
Deeks et al., 2003.
74
 The USPSTF criteria for randomized controlled trials is well 
established and has been used in the reviews upon which recommendations were made for 
breast cancer screening with mammography and PSA-based screening for prostate 
cancer.
2, 75
  The STROBE criteria was developed by a collaborative group including 
epidemiologists, methodologists, statisticians, researchers and journal editors.
73
  The 
Strobe Statement is used in journals such as the Annals of Internal Medicine, Archives of 
Internal Medicine and the Lancet. The criteria provided by Deeks et al. was used to further 
characterize internal validity and to ensure that a reasonable degree of continuity existed 
between quality grades determined through use of the two sets.   
Studies were given overall grades of good, fair or poor.  While a good study may 
have limitations, the overall strength of design was such it still produced results that were 
reliable and valid.  Conversely, a poor study was one in which the magnitude of bias was 
considerable, the results and conclusion were of very low certainty and, therefore, the 
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study contributed little overall value to the body of literature addressing our key questions.  
External validity was assessed by examining biological representativeness of the study 
participants, the size of the population studied, use of protocols for design and accurate 
use of both exposure status and diagnostic measures.  When reviewing quality, we created 
a separate document with only the study number and author in an attempt to minimize bias 
due to study population, results or journal title.  The STROBE statement and Deeks et al. 
are included in Appendix.  [Note: although we attempted to find randomized trials, we did 
not identify any with our search.  The following describes the components of the quality 
assessment for observational studies only.]  
Assigning Overall Quality Grade 
 Internal validity and external validity were each given ratings of poor, poor to fair, 
fair, fair to good, good.  Each subsequent category was given a point value (poor=1, poor 
to fair=2, etc.)  The total point value determined the overall quality grade.    A perfect 
hypothetical study would receive a score of 10, the worst hypothetical study would receive 
a score of 2.  Point values and grades were as follows: 5 points or less was POOR, 6 to 7 
points was FAIR, and 8 points and above were GOOD.  See Table 2 below for further 
description of scoring grade.  Studies that received POOR for both internal and external 
validity were not included in the quantitative synthesis of outcome assessment.  A 
description of these studies and reasons for grades of POOR for internal and external 
validity are provided in the Appendix.   
Table 2 Grading System for Overall Quality 
Point Ranges Overall Grade 
≤5 Poor 
6-7 Fair  
≥8 Good 
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Assessment of Internal Validity, Confounding, External Validity 
 Evaluation of internal validity included assessment of selection, measurement bias, and 
identification and adjustment for confounding.  Selection bias would be minimized in a study 
with the following characteristics in which the study population resembled the source population.  
There would also be less risk of selection bias in the studies in which groups (cases, controls; 
exposed, non-exposed) are similar and maintained with minimal dropouts (or no outcome).  
 Selection bias would be more pronounced in studies in which the participants were 
volunteers, recruited with other inadequate sampling method (consecutive assignment, referral 
for elevated PSA, status post radical prostatectomy or TURP), if participants differed in baseline 
characteristics, geographical setting, practice setting (specialty clinic, status-post surgery), or if 
participants refused, were lost to follow-up, or had varying levels of health care access and 
treatment options.  Measurement bias was a considerable concern when developing the quality 
assessment criteria because of the tendency for measures of TNM System staging, Gleason 
scores and prostate cancer specific-mortality to change over time.
50, 51
 Family history statuses 
collected by interview (surveys or in-person) or through medical records were subject to 
imprecision, but could be minimized by using a combination of methods.  Individual methods of 
questionnaire delivery were subject to different risks of bias.  Mailed questionnaires had a high 
susceptibility to selection bias as these participants had many barriers to successful participation 
in the study.  In person self-reports or in-person questionnaires (likely to have 
conducted/collected on-site) were less likely to be subject to selection bias, however any 
retrospectively collected data was vulnerable to recall bias.  In-person interviews were 
considered to be somewhat less susceptible to bias, but more susceptible than methods that cross-
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referenced with medical record documentation.
76, 77
  Additionally, men with particularly 
aggressive cancer (with or without a family history) may be unable to enroll in a study due to 
severity and rapidity of their disease (thus removing them from the population prior to study 
recruitment).   
 Each of our definitions of aggressive prostate cancer was susceptible to unequal, invalid 
and unreliable measurements, however bias could be minimized by using same measurement 
between both groups (histology for both aggressive and non-aggressive prostate cancer versus 
histology for some and cytology for others etc. or using symptoms for metastatic disease such as 
bone pain versus PET/CT for another group of participants to denote distant spread).  Although 
there is debate in the literature, cytologic and histologic are considered to be comparable in the 
diagnosis of prostate cancer.
78
  Measurement bias could be minimized by using the same 
measure for all cases, blinding and with centralized review.   
 Recall bias was a concern for measurement bias and possibly confounding.  Recall bias 
may act as a confounder because it is related to the exposure and outcome, is not a causal 
intermediate and is differentially distributed between groups.  Recall bias is likely to be more 
pronounced with retrospective studies and potentially controlled with proper methodology such 
as measuring family history at baseline rather than at a time after study initiation.   
Hyperawareness, hyper-vigilance, and subsequent excessive and or early screening, 
overdiagnosis (and thus exclusion) and overtreatment may act as confounders in prospective and 
retrospective studies.  Studies that provided well-structured protocol for PSA-based screening 
and biopsy may minimize this bias.  Statistical analyses employing multivariate models may also 
mitigate confounding. 
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 External validity determined the degree to which the results of a given study could 
reasonably be considered applicable to the general population of men in the United States with a 
family history of prostate cancer.  External validity would be low if the study population was 
representative of one small component of the socioeconomic distribution, localized to one 
geographic location, one ethnicity, consisted of a narrow age range, or included men who were at 
different levels of risk than men with positive family history in the general United States 
population.  Another concern to external validity was family history exposure in the study 
population in comparison to the general population, with the exposure potentially over-
represented in the study population (and possible source population in specialty clinics for 
example).   
Bias in Study Design 
 All study designs are subject to bias.  Though a good quality randomized trial is likely to 
have less bias than a cohort, case-control or cross-sectional study, respectively, a well done 
cohort design may provide more certainty than a poor randomized study.  This can be applied to 
all study designs, however in general, we considered the certainty of results to be greatest to least 
as the following: randomized studies, cohort, case-control and cross-sectional.  Again, because 
cross-sectional studies measuring exposure of family history had the capacity to approximate a 
longitudinal study, we did not exclude this design from inclusion.  Considering our key 
question(s) and clear challenges of identifying any randomized studies, we determined that 
prospective cohort studies would likely be least susceptible to bias, while a poor quality cross-
sectional would be most susceptible to bias.   
Data Collection 
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 Both reviewers independently examined each article meeting inclusion criteria for 
characteristics including study design, population, exposure, comparator group, study design, 
and outcomes.  The articles were filed in EndNote and Microsoft Excel (see Appendix).  
Data Synthesis 
 For all included studies, we applied quality criteria described above and extracted data on 
study population, exposure and outcome (see Appendix).  We reported by quality and also by 
outcome type (TNM Stage, Gleason score, PSA, mortality).  Our review does not include a 
multi-effect meta-analytical review of the literature, however the quality of evidence and results 
by outcome-type are provided along with a narrative review. Studies of higher quality will be 
weighted more heavily than studies of poorer quality.  For grading the strength of evidence we 
modified guidelines developed by Owens et al. (AHRQ Series Paper 5, 2010)
79
 for comparing 
medical interventions. 
Study Screening by Title and Abstract 
 I examined the results from the searches described above by abstract, noting study 
design, exposure and outcome assessment, and publication date.  A second reader did this 
as well, independently.  In an effort to include as many studies as possible for full-text 
review, exclusions were only made at this stage if it was clear that a study would not 
answer or was not relevant to our key question.  The majority of these excluded studies 
fell into one of three categories: studies of familial cancers other than prostate cancer, 
studies of risk factors for prostate cancer other than family history and studies that focused 
specifically on particular polymorphisms or permutations.  While valuable to 
understanding the key question, results of this latter category were filed and examined in 
the later sections (see Discussion), but did not contribute to the evaluation of risk of 
30 
 
family history in the general population.   At the time of independent review, if either of 
the reviewers determined that an abstract did not clearly fail to meet eligibility criteria, the 
entire body of the article was examined.  If the reviewers failed to agree on any article’s 
ability to meet criteria, the entire article was reviewed independently by a senior third 
reviewer. 
Study Exclusion by Full-Text Review 
 We excluded 25 studies at the full-text review stage.  Twenty of these 25 studies 
did not meet eligibility criteria with regards to outcome; they did not report or allow for 
derivation of aggressive disease. Although the studies evaluated correlation of family 
history and prostate cancer, the studies did not report characteristics of prostate cancer in 
such a way that aggressive disease could be assessed.  Most of these studies did not report 
a Gleason, TNM Stage or mortality (etc.) or described characteristics in such a way that 
limited utility (for example reporting a median PSA, median Gleason etc.).   
Results  
Search Results 
 I searched MEDLINE and 
EMBASE on February 22, 2012 using 
search strategies developed with the 
assistance of a library science expert (see 
Acknowledgements) at Health Sciences 
Library at UNC-Chapel Hill.  Our initial 
search yielded 8,706 studies (912 studies 
from MEDLINE and 368 from Embase).  
Table 3 Studies included in qualitative and narrative review 
by nationality 
Authors Publication 
Year 
Country of 
Publication 
Ahn et al 2008 Finland 
Rodriguez et al 1997 United States 
Thompson et al 2007 United States 
Thompson et al 2006 United States 
Makinen et al 2002 Europe* 
Yen-Chen et al 2008 United States 
Spangler et al  2005 United States 
Valeri et al  2000 France 
Kotis et al 2002 United States 
Schuurman et 
al 
1999 Finland 
Rohrmann et al 2003 United States 
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We added an additional 128 studies through consultation with experts and hand search of the 38 
references meeting initial eligibility.  A total of 780 studies remained for screening after 
removing duplicates.  A flow chart of our study identification process is described in Figure 2.  
After screening by title and abstract (described below), a total of 38 studies underwent full-text 
review.  An additional 25 studies were excluded because of an inability to meet our PECOTTS 
criteria upon closer examination (described below).  Thirteen studies met eligibility requirements 
and were reviewed qualitatively.  Of these 13, 2 studies were of poor quality due to poor internal 
and external validity and/or possessed a “fatal flaw” in methodology.  The 11 remaining studies 
were used in a narrative/quantitative review of the literature to assess our key questions.   
Table 4. Summary of Quality Assessment for Included Studies 
Authors Study Design 
Internal 
Validity 
External 
Validity 
Overall 
Grade 
Ahn et al Retrospective Cohort Fair 
Poor to 
Fair 
Fair 
 
Rodriguez et al 
Prospective Cohort 
within a cross-sectional 
Poor to Fair Fair Fair 
Thompson et al 
(finasteride) 
Nested Case-Control Poor to Fair Poor Poor 
Thompson et al 
(placebo) 
Nested Case-Control Fair to Good 
Poor to 
Fair 
Fair 
Makinen et al 
Cross-sectional within 
a cohort 
Poor to Fair 
Poor to 
Fair 
Poor 
Yen-Chen et al Retrospective Cohort Fair 
Poor to 
Fair 
Fair 
Rohrmann et al Case-Control Fair Poor Poor 
Spangler et al Case-Control Poor to Fair Poor Poor 
Valeri et al Case-Control Fair Poor Poor 
Kotsis Case-Control Fair to Good Poor Poor 
Schuurman et 
al 
Nested Case-Control Poor Poor Poor 
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Table 5. Results from included studies by study design, quality and outcome type 
Authors Study Design 
Outcome 
Type 
Overall 
Quality 
Results 
 
Ahn 
Retrospective 
Cohort 
Gleason ≥7, 
TNM Stage 
Fair 
 
RRGleason Not significant 
RRTNM 4.16 (2.67-6.49) 
 
Rodriguez 
Prospective Cohort 
within a cross-
sectional 
Prostate 
cancer-
specific 
mortality 
Fair 
RR (by Age) 
<65: 1.46 (0.80-2.67) 
65-69: 1.89 (0.19-2.99) 
70-74: 1.90 (1.26-2.87) 
75-79: 1.88 (1.27-2.77) 
≥80: 1.02 (0.62-1.68) 
Thompson 
(finasteride) 
Nested Case-
Control 
Gleason ≥7 Poor 
ORGleason : not significant 
Thompson 
(placebo) 
Nested Case-
Control 
Gleason ≥7 Fair 
ORGleason : not significant 
Makinen 
Cross-sectional 
within a cohort 
Gleason ≥7, 
T3a, T3b, M1 
Poor 
  RRGleason 0.6 (0.2-2.0) 
RRTNM 1.0 (0.3-3.0) 
Yen-Chen 
Retrospective 
Cohort 
Gleason ≥8, 
T3b or higher 
Fair 
RRGleason 1.74 (1.50-2.02) 
RRTNM 1.76 (1.37-2.26) 
Rohrmann Case-Control 
Gleason ≥7, 
T3a or higher 
Poor 
ORGleason 0.73 (0.45-1.18) 
RRTNM 0.8 (0.5-1.28) 
Spangler Case-Control 
Gleason ≥7, 
T3a or higher 
Poor 
ORGleason 0.79 (0.56-1.12) 
ORT3a 1.30 (0.89-1.91) 
ORT3b 1.91 (0.98-3.73) 
ORM1 1.04 (0.26-4.22) 
Valeri Case-Control Gleason ≥7 Poor 
ORGleason Not significant 
ORTNM Not significant 
Kotsis Case-Control Gleason <7 Poor ORGleason 1.96 (1.13-3.41) 
Schuurman 
et al 
Case-Cohort Gleason ≥7 Poor 
RRTNM (fathers) 1.98 (0.93-
4.24) 
RRTNM (brothers) 5.33 (1.36-
20.85)* 
 
Table 3.  Absolute risk and attributable risk proportion for calculated from cohort studies 
Study  Absolute Risk by Outcome Type Attributable Risk Proportion  
Ahn Gleason 
ARexposed 0.02 
ARnon-exposed 0.01 
TNM Stage  
ARexposed 0.04 
ARnon-exposed 0.01 
ARP (Gleason) 5.9 cases over 12 years 
ARP (TNM) 17.6 cases over 12 years 
Rodriguez Prostate cancer-death/person-years 
ARexposed 0.0005; ARnon-exposed 0.0008 
ARP 0.04 per 125 person-years 
Yen-Chen Gleason 
ARexposed 0.010 
TNM Stage 
ARexposed 0.015 
ARPGleason 20.9 cases over 14 years 
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ARnon-exposed 0.006 ARnon-exposed 0.010 ARPTNM 26.2 cases over 14 years 
 
Synthesis of Study Design and Population 
 A total of 11 studies were included for quality assessment.  Overall, there were 3 
cohort studies, 7 case-control studies and 1 cross-sectional study within a cohort.  Two of 
the 3 cohort studies were derived from large-scale, population-based cohorts designed to 
collect data for multiple purposes.  The other cohort was derived from both the 
intervention and control arm of a randomized controlled study.  Notably, none of the 
cohort studies were designed specifically to answer our key question.  However, each 
provided data for assessment of rate ratios, absolute risk and attributable risk of exposure 
for our outcome.  Three case-control studies and the cross-sectional study were nested in 
randomized controlled trials.  The other 4 case-control studies were single institution-
based studies at specialty clinics.  As described in Table 3, four of the studies were based 
in Europe, seven were conducted with participants from the United States.   
Demographics 
 In general, African American men were underrepresented in all of the studies, 
though study populations within the United States included a small percentage of African 
Americans (<5%).  Men with positive family history tended to be over-represented in 
case-control studies relative to the general United States population.  Prevalence of 
positive family history in cohort studies more closely approximated that in the general 
United States population.  Two case-control studies consisted only of men aged less than 
56.  Most study populations had age ranges of 50-70, although the range extended from 40 
to over 80 years.  A large majority (estimated 70%) of men were between ages 50 and 70.  
Of note, two of the nested case-control studies were from the intervention and control arm 
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of a randomized trial.  Baseline age of participants and socioeconomic variables were 
adjusted for in most studies.   
Screening Prior to Enrollment  
 Screening rates prior to enrollment varied within the study populations.   
The various populations were accounted for in the quality assessment with regards to 
selection bias (if the study population did not represent the base/source population) and 
external validity (if either the source or the study population was not comparable to the 
general United States population).  Although only 3 studies specifically address screening, 
rates are likely predictable based on nationality of the study population.  All three studies 
to address screening rates in the methods section had high screening rates, and other 
United States study populations also likely had high rates per guidelines existing at that 
time.  One European study was the control arm of the ERSPC trial and thus had no 
screening.  The other European studies also likely had low levels of screening per 
guidelines. The implications of the various degrees of screening are unclear.  For most 
studies, a prior diagnosis of prostate cancer resulted in exclusion, likely regardless of 
histologic grade or stage.  Because men with a family history are more likely to be 
screened at an earlier age in the United States, it is possible that this would result in a bias 
towards the null.  However, it is also possible that by excluding men with (most likely – 
statistically) benign disease from participation, the incidence of aggressive disease within 
the “exposed” study population would be concentrated and thus cause a bias away from 
the null.  Moreover, the bias is complicated by the unknown impact of PSA-based 
screening on incidence and mortality of aggressive prostate cancer.   
Exposure 
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 Documentation of family history for most of the studies included in the review 
were by in-person interviews or questionnaires either in-person (given by volunteers) or 
self-administered.  Six studies obtained in-person interview or self-administered 
questionnaire prior to study enrollment, the remaining 5 (all case-control) collected family 
history after outcome measure. Five of the 11 studies collected self-administered 
questionnaires, 4 studies obtained in-person interview or in-person questionnaires.  Two of 
the studies used multiple methods to cross-check family history, one in-person interview 
and medical records, the other mailed questionnaires and had telephone follow-up.  
Outcomes  
 The outcomes of each study are provided in Table 5.  Outcomes for aggressive 
disease were reasonably comparable across study types and study populations.  However, 
given the variability of diagnostic modalities, screening recommendations and temporal 
trends, a meta-analysis was felt to be inappropriate due to high risk of imprecision and 
inaccuracy when coalescing variable characteristics.     
Gleason Score 
 Nine studies reported aggressive disease by Gleason score. Of these, 2 of the 
studies were cohort, 7 were case-control and 1 was cross-sectional.  Nine of the studies 
defined aggressive prostate cancer as greater than or equal to 7.  One study reported 
aggressive Gleason as greater than 7.  Overall, 2 studies reported increased relative risk of 
aggressive disease in men with affected first-degree relative compared to men without 
positive family history and 8 studies reported no statistical significance.   
 Of the 2 cohort studies, 1 reported a risk ratio of 1.74 (1.50-2.02), the other 
reported no statistical significance. Both cohort studies were fair quality.  For cohort 
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reporting increased relative risk (Yen-Chen et al.), we calculated a risk difference of 0.004 
and an attributable risk of 20.9 cases over 14 years.  All 6 case-controls studies reported 
no statistical difference for odds of aggressive cancer defined by Gleason.  One of these 
case-control studies was of fair quality, five were poor quality.  One fair quality cross-
sectional study within the ERSPC cohort also reported no statistical significance.   
Summary Report for Gleason 
 Two cohort studies; one fair quality reports increased relative risk, one fair quality 
reports no difference 
 Six case-control studies; one fair and five poor quality report no difference, 
 One cross-sectional; fair quality reports no difference 
TNM Stage 
 Seven of the included studies reported aggressive disease by TNM Stage.  Of 
these, 2 were cohorts, 4 were case-control and 1 was cross-sectional.  Overall, 3 studies 
showed family history was significantly associated with aggressive prostate cancer.  Two 
cohort studies, Ahn et al. showed relative risk of 4.16 (2.67-6.49) and Yen-Chen et al. 
reported relative risk of 1.76 (1.37-2.26) of aggressive cancer for men with an affected 
first-degree relative compared to men without family history.  We calculated absolute risk 
for Ahn et al. of 0.04 for aggressive disease in the exposed compared to 0.01 in the non-
exposed, corresponding to an attributable risk of 17.6 cases over 12 years.  For Yen-Chen 
et al., the absolute risk in the exposed and non-exposed was 0.015 and 0.010, respectively, 
for TNM defined aggressive disease.  We calculated the risk of aggressive disease 
attributable to positive family history  to be 26.2 cases over 14 years.  
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 One poor quality case-cohort reported odds of reported relative risk of 5.33 (1.36-
20.85) for men with affected brothers, but no significance for men with affected fathers.  
Three poor quality case-control studies and one fair quality case-cohort study reported no 
statistically elevated risk for aggressive disease defined by T3 overall, T3a, T3b and 
metastatic disease compared to men without family history.   
Summary Report for TNM Stage  
 Two fair quality cohort studies show increased risk – relative risk of 4.16 and 1.76, 
absolute risk difference of 0.03 and 0.005, attributable risk of 17.6 cases over 12 
years and 26.2 cases over 14 years 
 One poor quality case-cohort shows increased risk, three poor quality case-control 
and one fair quality cross-sectional study show no increase risk 
PSA Levels at Diagnosis 
 One poor quality case-control (Norrish) study reported PSA levels of 20ng/mL or 
more at the time of diagnosis.  Authors found PSA of 20 ng/mL or more to be less 
common in men with family history of prostate cancer than in men without such history.  
However, the study had several important limitations and was excluded from analysis  
(Table XXXX).   
Summary Report for Pretreatment PSA 
 One case-control study met eligibility, but was excluded due to poor quality 
Prostate Cancer-Specific Mortality 
 One fair quality cohort study reported prostate cancer-specific mortality 
(Rodriguez).  Authors reported relative-risk of prostate cancer-specific mortality, but not 
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absolute risk.  Relative risk of prostate cancer-specific mortality was higher in men aged 
70-74 and men aged 75-79 with family history of prostate cancer compared to men 
without such history.  However, there was no difference in relative risk for men aged less 
than 70 and more than 79 years.  We calculated a risk difference of 0.0003 and an 
attributable risk of 0.04 per 125 person-years for aggressive disease given positive family 
history.   
Summary Report for Prostate Cancer-Specific Mortality 
 One fair quality cohort showed increased relative risk for men ages 70-79, risk 
difference was small (0.0003) for all ages included, attributable risk of 0.04 per 
125 person-years 
Summary of Overall Outcomes 
 All 3 cohort studies showed some increase in risk for at least a subset of the study 
population, however the risk difference and attributable risk was small.   
 Seven non-cohort studies showed no increase in risk magnitude, 1 showed 
increased risk for men with affected brothers but not fathers.  
Synthesis of Evidence 
 We found patterns in the evidence reported by included studies.  Cohort studies 
were more likely to report increase risk and non-cohort studies more likely to show no 
difference in risk.  Gleason-defined outcomes were more likely to show no difference than 
TNM-defined outcomes.  Studies with specialty clinic populations were all case-control 
studies and were more likely have smaller numbers, report no difference and have shorter 
follow-up.  Cohort studies were more likely to be more representative of the general 
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population of men and have longer follow-up.  Studies with longer follow-up were more 
likely to report increased risk, but for all of these studies the absolute risk of the exposed 
was similar to that of the non-exposed.  There was a concern that Gleason- and TNM-
defined aggressive cancer would show increased incidence rates in later studies compared 
to earlier studies (due to upward migration and increased use, capacity of imaging 
technology), however the extent to which this was evident is unclear.   
Strength of Evidence  
Risk of Bias 
 Although observational studies are generally considered inferior to randomized 
trials in hierarchy of study design to assess effect of a “risk factor,” a methodologically 
conscientious cohort or case-control study has the potential to produce unbiased results.   
In the 11 studies included in the quantitative assessment, 3 were cohort, 7 were case-
control and 1 was cross-sectional.  Application of quality criteria yielded 3 fair quality 
cohort studies, 1 fair and 6 poor case-control studies and 1 fair quality cross-sectional 
study.  We did not set an a priori minimum percentage of good, fair or poor quality 
studies to determine low, medium or high risk of bias.  However, given our knowledge of 
study quality and critical appraisal, we concluded that 55% poor, 45% fair and 0% good 
quality most likely denotes a high risk of bias in the evidence.   
Consistency 
 Consistency was determined by examining the effect size – whether most or all 
studies fell on the “same side” of the null with regard to the outcomes.  If the most or all 
of the studies reported an effect (a positive association of risk), consistency was also 
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determined by the range of the effect size.  A narrow range of effect size would denote 
consistency while a wide range of effect size would indicate inconsistency.   
 Of 9 studies reporting Gleason score, 1 showed increase in relative risk, 8 showed 
no difference.  Of 7 studies reporting aggressive disease by TNM Stage, 3 showed 
increase in relative risk, 4 showed no difference.  The 1 study reporting PSA was 
excluded.  The study reporting prostate cancer-specific mortality showed increased 
relative risk for men aged 70-79.
80
   
 In summary, the evidence is inconsistent.  While Gleason-based outcomes were 
more consistent in proving the null, it did not do so for one fair quality cohort.  TNM 
Stage was determined to be inconsistent.  Only one study reported prostate cancer-specific 
mortality and it showed only increased risk for one men aged 70-74 and 75-79.  Of note, 
screening in this group has previously been found to have less benefit that harm.
81
  
Therefore, overall the evidence was felt to be inconsistent.   
Directness 
 In adopting our criteria for “aggressive” prostate cancer, we designed our review to 
be limited with regard to directness.  Although Gleason scores of 7, 8 or more and TNM 
Stage T3 or above have been shown to be associated with greater risk of death from 
prostate cancer,
51, 82
 the predictors themselves are intermediates or surrogates for clinically 
important outcomes (in this case prostate cancer-specific mortality or overall mortality).  
Ten of 11 included studies reported only clinical intermediates.  Prostate cancer-specific 
mortality, though superior to the other surrogates, is also inferior to overall mortality with 
regard to directness.  Overall, the evidence is indirect.   
Precision 
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 The degree of certainty for the estimates of effect or lack thereof determines 
precision and precise estimate is one which is clinically useful.  With regard to Gleason 
and TNM Stage, we feel there is a high degree of certainty that – in the absence of clinical 
or patient-specific context – a man reporting family history of prostate cancer in a first-
degree relative is not in and of itself a reasonable justification to consider that man to be at 
increased relative risk of aggressive – clinically significant – prostate cancer compared to 
a man without such a family history.   
Plausible Confounding 
 Observational studies examining effect of family history and aggressive disease 
have risk of confounding that may work in a direction opposite to the observed effect.  
This would occur in the form of hyper-awareness, artificial over-estimation of risk 
perception, overdiagnosis and overtreatment of relatively benign disease that is not 
clinically significant in regards to morbidity or mortality.  A large percentage of men who 
have histologic prostate cancer will never have clinically significant disease.  Men with 
affected relatives are more likely to start PSA-based screening earlier and more often.  
Considering the inaccuracy of the PSA test, men with positive family histories are more 
likely to receive biopsy with increased frequency of PSA-based screening.  Because 
histologic prostate cancer that is clinically insignificant is prevalent – men with family 
history are more likely to receive diagnosis of prostate cancer and therefore will not meet 
criteria for inclusion of studies examining family history and prostate cancer.  The men 
with affected relatives who do not receive diagnoses of prostate cancer therefore, may 
represent a population in which the frequency of benign disease is concentrated, thus 
moving the observed effect towards the null.   
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 Conversely, confounding could also exist that works away from the null.  Certain 
prostate cancers are aggressive and it is reasonable to speculate that there are genetic 
components to this (and all) cancers.  Aggressive prostate cancers may be less likely to be 
detected with regular PSA-based testing, while less aggressive cancers may be more likely 
to be detected.  Thus, men with affected relatives who may have higher a likelihood of 
aggressive disease may be over-represented in the population (because men with less 
aggressive disease have been excluded with PSA-based screening) and cause an 
amplification of an effect that is away from the null.   
Publication Bias 
 Publication bias is a concern in any systematic review.  For this and most reviews, 
publication bias would most likely have a tendency to move the observed effect away 
from the null.  However, because family history of prostate cancer has been considered a 
clinically reliable risk factor for overall prostate cancer since 1960,
83
 it may be that a 
publication bias would actually favor the null. See the Discussion for further details and 
methods we used to address and minimize publication bias. 
Discussion 
 In our review of the literature, we found that the evidence on relative and absolute 
risk of aggressive prostate cancer in men with a positive family history in at least one first-
degree relative is mixed.   Furthermore, the quality of evidence examining the relationship 
of family history and aggressive disease is poor to fair overall.   
Summary of Evidence 
 Eleven studies were included in the narrative assessment.  Three studies were 
cohort studies, each was of fair quality.  Evidence from the cohort studies on Gleason-
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defined, TNM-defined and prostate cancer specific mortality is mixed.  We calculated 
absolute risk and attributable risk for studies reporting increased relative risk for 
aggressive disease in men with affected relatives compared to those without; we found 
absolute risk difference and attributable risk to be small and unlikely to change the 
benefit-to-harms ratio described by the USPSTF regarding the general population (see 
Clinical Implications).
2
  Seven case-control (1 fair, 6 poor quality) and one fair quality 
cross-sectional study also report mixed findings, but most show no statistically significant 
increase in risk magnitude of aggressive prostate cancer for men with a family history.  
The evidence indicates that if it exists, the magnitude to which men with affected first-
degree relatives are at increased risk for aggressive prostate cancer is likely small.   
Congruency with Existing Literature 
 As mentioned in the introduction, four formal meta-analyses and two informal 
reviews have assessed the relationship between overall prostate cancer and family history.  
In contrast to previous reviews, this review exclusively assesses risk associated with only 
aggressive prostate cancer.  All previous reviews have found men with family history to 
have increased relative risk for prostate cancer than men without family history.  
Importantly, reviews by Bruner
9
 and Zeegers
7
 stratify risk of having an affected brother or 
father and Johns
67
 stratifies by number of affected first-degree relatives when assessing 
evidence on overall prostate cancer.  We did not stratify our results in this review and 
discuss the clinical implications of this below (see Clinical Implications).     
 Overall, we found that evidence of increased risk of aggressive prostate cancer in 
men with a family history is incongruent with evidence of increased risk of overall 
prostate cancer and family history.   
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Congruency with Recommendations of Professional Societies 
 Importantly, our review informs but does not evaluate PSA-based screening in 
men with at least one affected first-degree relative.  However, we extrapolated our finding 
in terms of implication for such screening modalities.  In doing so, we found the evidence 
to be incongruent with current recommendations from the American Urology Association 
and the American Cancer Society which encourage men with a positive family history to 
undergo screening at an earlier age.  Our review is congruent with the United States 
Preventive Services Task Force recommendation against PSA-based screening in men 
with a positive family history.  While previous systematic reviews and meta-analyses 
show that a positive family history is associated with increased risk for overall prostate 
cancer, we have found inadequate evidence that the association persists for aggressive 
prostate cancer.  As described in the Introduction, men with a family history significant 
for prostate cancer are more likely to undergo earlier and more frequent screening 
compared to men without such history.
84
  This tendency may be attributable to 
recommendations from these professional societies and or an increased anxiety or 
awareness of prostate cancer.  As a result of these factors, men with a positive family 
history may be more likely to suffer harms of overdiagnosis and overtreatment than men 
in the general population (see Clinical Implications).   
Congruency with Other Commentaries 
 Several authors have suggested risk stratification to determine whether and how 
frequent men should receive PSA-based screening.
13-15, 69, 85
 Family history is a component 
of risk calculators that attempt to estimate risk of prostate cancer on biopsy.  Our review 
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of the evidence is incongruent with use of family history in risk calculators or in risk 
stratification schemes.   
Limitations of the Review 
Publication Bias 
 Our review has several limitations.  Publication bias is a common short-coming of 
systematic reviews and if present would tend to push our findings away from the null (see 
Strength of Evidence).  To evaluate for publication bias, we searched for unpublished 
abstracts in both the American Society of Clinical Oncology and Genitourinary 
International Symposiums from 2000 to 2012.  We identified one unpublished abstract 
from the 2005 ASCO Annual Meeting reporting an earlier age at diagnosis in black men 
with a positive family history in at least one first-degree relative; however, we were not 
able to determine whether criteria for aggressive disease was met.
86
  It is unlikely that 
additional unpublished data would provide convincing evidence to change our conclusion.  
Variable Populations 
 As described in our introduction, this review is limited in that it does not report 
evidence on relative or absolute risk for men with more than one first-degree relative.  
Discussed in further detail in the Introduction and Clinical Implications sections, the 
genetics of prostate cancer are complex and incompletely understood.  Several studies 
have reported differences in risk depending on type of first-degree relative, with many 
describing higher risk in brothers compared to fathers.
9
  Although, this may be attributable 
to increased awareness for men whose sibling rather than father has been diagnosed with 
prostate cancer, other factors may also play a role.   
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 We also did not define criteria for age at diagnosis in first-degree relative.  In not 
defining age criteria for family history, our review is at risk of differential 
misclassification of family history in that we may have considered a family history to be 
positive even if the first-degree family member was diagnosed at an advanced age at 
which rates of overdiagnosis are highest.
87, 88
  We considered including only those studies 
that provided age of diagnosis of 70 years or less in the first-degree relative.  However, we 
determined that this restriction presented a risk of narrowing our search that was greater 
than the potential benefit of minimizing a bias toward the null.  Our review was also 
limited in that it did not describe risk of African American men with positive family 
history.  African American men are underrepresented or not represented in all of the 
studies included in this review.   
 Another limitation is the variability of the study populations of included (and 
excluded) studies, not only by geographic location within the United States, but 
internationally as well.  We considered excluding studies on populations outside of the 
United States a priori, however we determined that this would not be a reasonable course 
of action due to the fact that the results from the ERSPC Trial, conducted exclusively in 
European countries, have had implications for screening practice recommendations in the 
United States.  There was also variability in prior screening throughout included study 
populations.  Higher rates of screening prior to study enrollment would most likely cause a 
bias towards the null, as men who had been previously diagnosed with prostate cancer 
were generally excluded or unable to participate.  However, as discussed in Strength of 
Evidence, there is also a potential for bias in the direction away from the null.  
Clinical Intermediates and Follow-Up 
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 Use of clinical intermediaries is another limitation.  Although Gleason Score, 
TNM Stage and PSA at time of diagnosis are correlated with disease aggressiveness and 
therefore mortality, they are not necessarily clinically meaningful in and of themselves.  
Only one of the included studies reported prostate cancer-specific mortality and there were 
no studies reporting magnitude of risk for overall mortality.   
Follow-up Time 
 Follow-up time was also a limitation of this study.  The median follow-up time for 
the 11 studies included in narrative assessment varied.  For cohort studies the follow-up 
tended to be 9 years or longer, but for non-cohort studies it tended to be fewer than 9 
years.  Overall, prostate cancer is an indolent disease and as a result follow-up periods less 
than 10 years may not be adequate to assess differences in outcomes.  However, it is likely 
that aggressive prostate cancer is not indolent and therefore studies with shorter follow-up 
may be needed to assess our key question.  
Harms 
 The most important limitation with regards to clinical application was inability to 
assess harms (see Clinical Implication).  Overall, we found insufficient evidence to 
consider family history as a risk factor for aggressive prostate cancer.  If men with a 
family history in the general population are not at increased risk for aggressive disease, 
they may be at high-risk for suffering harms from prostate cancer screening in the form of 
earlier overdiagnosis and overtreatment due to unsubstantiated increased risk perception.  
Thus, frequency of harm outcomes may be amplified in men with affected relatives and 
the harms may outweigh the benefits of PSA-based screening to an even greater extent 
than in the general population.  However, while this review does not find sufficient 
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evidence of increased risk, it also did not find sufficient evidence for no increase in risk 
(see Clinical Implications).   
Clinical Implications 
 Although there is robust evidence that family history increases relative risk for 
overall prostate cancer, the evidence is insufficient to extend this or any increase in risk to 
aggressive prostate cancer without further characterization of a man’s “positive” family 
history.  In other words, the benefits are likely to be outweighed by the harms if screening 
is recommended for a man reporting a positive family history if the clinician does not  
obtain number and age of diagnosis in affected family members, relatedness of affected 
family members and the clinical characteristics (if possible) of the affected family 
member’s prostate cancer (age at diagnosis and cause of mortality).  Because of the 
magnitude of overdiagnosis of prostate cancer in the PSA-era, men with family history of 
clinically insignificant prostate cancer are at a high risk for overestimating perception of 
risk, suffering harms as a result of earlier and more frequent screening and unnecessary 
treatment in the absence of evidence showing either increase risk of aggressive cancer or 
ability of PSA-based screening to provide benefit if an increase risk exists.   
 Clearly, Bayesian probability will play a role in any man reporting more than one 
first-degree relative with prostate cancer even in the absence of further characterization, as 
this could indicate familial inheritance patterns.  Importantly, this review considers 
evidence supporting increased risk of aggressive prostate cancer in the “general population 
with a positive family history.”  Family studies have demonstrated 5- and 11- fold increase 
risk of overall prostate cancer in men with two or three affected first-degree relatives 
compared to men without such history, respectively.
24, 89
  Studies have also reported 
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increase risk for overall prostate cancer in men carrying BRCA1 or BRCA2 mutations.
90
 
However, as described in the introduction, the study of prostate cancer genetics, while 
rapidly developing, appears to be many years from validating predisposition for 
aggressive disease, determining prevalence and assessing benefits and harms of PSA-
based screening in these populations.   
Potential Protective Mechanism for Patients 
 A potential mechanism to protect patients from overdiagnosis and overtreatment of 
clinically insignificant prostate cancer secondary to positive family history would be to 
require further qualification for a family history to be considered positive.  Similar to 
measures used in cardiovascular disease (men should begin screening at earlier ages if 
they have a family history of serious cardiovascular event prior to age 50 etc.), such 
qualifications could entail follow up questions to elicit age of diagnosis of first-degree 
relative and if the affected relative died from or with the disease.  If employed in 
conjunction with clinician intuition and judgment, such a mechanism may protect patients 
who have had a first-degree relative diagnosed with clinically insignificant prostate cancer 
from harms of overscreening, overdiagnosis and overtreatment.   
Implications for Future Research 
 An important area for further exploration include basic science and translational 
research with aims to delineate the distinction of a family history of “overdiagnosed” 
prostate cancer from a family history of clinically significant, or aggressive prostate 
cancer.  It follows intuitively, in the context of our evolving understanding of cancer 
biology, that there may be certain forms of prostate cancer that are both aggressive and 
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heritable.  Perhaps the presence of such subtypes in some, but not other populations 
contributes to the mixed evidence presented in this review.   
 As described in the USPSTF recommendation statement and discussed in the 
Introduction, this review is one component of potential screen-based preventative 
measures.  If there are groups of men who, upon further research, are found to have 
aggressive subtypes of prostate cancer that are also heritable, we would also need 
randomized controlled trials of PSA-based screening in these groups to determine the 
magnitude of mortality benefit – if one exists – and if it outweighs risk of harms.  One 
concern is that aggressive tumors are either too rapidly progressive to be detected with 
annual or biennial PSA-based screening or that the tumors are undifferentiated and do not 
produce PSA thus limiting the usefulness of PSA-based screening.  Alternatively, 
randomized controlled trials are also needed to determine if screening all men with a fully-
characterized family history of aggressive prostate cancer in a first-degree relative – even 
without further elucidation of aggressive cancer subtypes – would provide benefits that 
outweighed harms of screening.   
 A final area of considerable importance for future research is further characterizing 
the harms of prostate cancer screening including patient anxiety (labeling, active 
surveillance, biopsy), anxiety, pain and complications of biopsy, and likelihood and 
consequences of unnecessary treatment.  A systematic review of the literature to determine 
the evidence of harms of prostate cancer screening would be especially important for men 
with a family history as it is likely that these men represent a particularly vulnerable group 
in whom the harms of screening may be concentrated.   
Conclusion 
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 In this review we assessed the evidence for our key question:  
What is the relative and absolute risk of aggressive prostate cancer in men with at a family 
history of prostate cancer in at least one first-degree relative compared to men without 
such history?  
We found that there is mixed, poor and overall insufficient evidence that men 
with a positive family history are at an increased risk of aggressive – clinically 
significant – prostate cancer relative to men without such history.   
Furthermore, we feel that as a result of this evidence, the benefits of PSA-based screening 
in these men without further characterization of the number, age of diagnosis and clinical 
impact of the affected first-degree family member is unlikely to outweigh risk of harms.  
Due to the potential overestimation of perceived risk, men with a “poorly characterized” 
positive family history of prostate may represent an especially vulnerable population at 
high-risk for harms of overdiagnosis and overtreatment.   
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Appendix 1 
 Table 4 – Description of reasons for exclusions based on quality 
Study Reason For Exclusion – Fatal Flaws 
Cerhan et al., 1999 
Number of cases of aggressive prostate cancer is too 
low to contribute in a meaningful way (n=2).  Statistical 
models adjusted for variables for unclear reasons in 
assessing aggressive disease, the degree of uncertainty 
was substantial given lack of power and the poor 
statistical methodology  
Norrish et al., 1999 No description of statistical methodologies or 
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adjustments for age or other covariates described; Power 
is insufficient for aggressive disease (n=3). 
 
Table 5.  Outcomes by type, quality, study design 
Author, year Source  Study  Exposure 
Ahn et al, 
2008 
The Alpha-tocopherol, beta-
carotene cancer prevention 
Study 
19,652 male smokers aged 50–
69 years in southwestern 
Finland  
Self-report with 
baseline 
questionnaire 
prior to entry 
Rodriguez et 
al., 1997 
508,576 males in the Cancer 
prevention study (ACS) 
enrolled by volunteers in all 
50 states in 1982 
481,011 men with no prior 
history enrolled by volunteers  
In-person 
questionnaire 
given by 
volunteers at set 
times during 
original study 
Thompson 
et al., 2006 
18,882 men 55 or older with 
normal DRE and PSA less 
than 3 randomly assigned to 
finasteride or placebo for 7 
years 
5519 men from the placebo 
group who underwent biopsy 
at end of study or due to rising 
PSA 
In-person 
interview at 
time of biopsy 
Thompson 
et al., 2007 
18,882 men 55 or older with 
normal DRE and PSA less 
than 3 randomly assigned to 
finasteride or placebo for 7 
years  
N=5,675 from 9459 
randomized to finasteride arm  
who underwent biopsy at end 
of study or due to rising PSA 
In-person 
interview at 
time of biopsy 
Schuurman, 
et al 1999 
58,279 men 55-69 from 204 
municipalities in Finland 
(data from the Netherlands 
Cohort Study (assessing diet 
and cancer).
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Cases were men with overall 
prostate cancer at 6.3 years, 
controls were randomly 
sampled from cohort 
Self-
administered 
questionnaire at 
baseline 
Yen-Chen et 
al, 2008 
51,529 male health 
professionals in the Health 
Professionals Follow-Up 
Study  
Subcohort of the HPFS study; 
42,144 participants provided 
data on family history; medical 
history  
Questionnaire; 
follow-up 
questionnaires, 
medical 
records; 
interview of 
family members 
Spangler et 
al, 2005 
Men in Pennsylvania aged 
40 and over diagnosed with 
prostate cancer 
All participating men 
diagnosed with prostate cancer 
at the UPHS (PENN) urologic 
oncology department clinics  
In-person 
interview after 
referral 
Makinen et 
al., 2002 
80,000 men aged 55 to 67 
from the population register 
from 1996-1999; part of the 
20,311  men randomized to the 
screening arm 
Self-
administered 
questionnaire 
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ERSPC (the finish center) (prior to 
screening) 
Kotsis et al., 
2002 
Middle aged men with 
access to health care and 
well-connected to 
specialists, recruited to 
study 
Men less than 55 referred to 
University of Michigan for 
participation in the Prostate 
Cancer Genetics Project. 
Questionnaire, 
follow-up with 
medical 
records;  
Valeri et al, 
2000 
Men in France referred to 
urology departments for 
newly diagnosed prostate 
cancer  
801 consecutive CaP probands 
treated in three French urology 
departments between 1994-
1997 
In-person 
interview after 
referral 
Rohrmann 
et al., 2003 
Men in the Baltimore area 
diagnosed with prostate 
cancer who underwent 
radical prostatectomy 
between 1992 and 1999 
498 of 1,544 consecutive men 
who underwent radical 
prostatectomy with a single 
surgeon who were under the 
age of 55 
 
Mailed 
questionnaire to 
all 498 men 
with follow-up 
telephone 
reminder 
 
Figure 3. Independent description of study population, eligibility criteria and quality 
Ahn et al., 2008
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Study Design Retrospective Cohort 
Source Population The Alpha-tocopherol, beta-carotene cancer prevention Study; a 
placebo-control study; 29,133 eligible middle aged male smokers in 
Finland 
Inclusion Criteria Male age 50-69 volunteered to be randomized between 1985 and 
1988.  Unable to obtain access to original methodology  
Exclusion Criteria History of any malignancy other than non-melanoma cancer of skin 
or carcinoma in situ, severe angina, chronic renal insufficiency, liver 
cirrhosis, chronic alcoholism, anticoagulant therapy, other medical 
problems that might limit participation and any use of the following 
supplements - vitamin E, vitamin A, beta carotene 
Study Population 19,652 men aged 50–69 years in southwestern Finland who smoked 
at least 5 cigarettes per day men with complete data from the 
original trial; No specific reference to screening in groups; prior 
screening likely minimal, intra-study screening likely minimal 
(European nationality) 
Risk Factors Consistent 
Between Groups  
No appreciable differences between groups (exposed, non-exposed); 
both groups appear to have same risk of developing outcome 
Attrition High (>20%) and Unequal (>15%): 52% of non-exposed, 95% of 
exposed had outcome measurements at 19 years overall follow-up 
(unable to identify median follow-up for non-exposed or overall 
cohort) 
Measurement of Self-report of participants prior to entry 
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exposure 
Measurement of 
outcomes 
Cases were ascertained by Finish Cancer Registry during the study 
follow-up, with additional centralized record reviews through April 
1999.  Medical records of each prostate cancer case diagnosed 
through April 1999 were centrally reviewed by 2 study oncologists 
to confirm the diagnosis and stage. In addition, the histopathologic 
and cytological specimens of the cases were reviewed by study 
pathologists during the trial and post-trial periods (56% of total 
cases). 
Statistical Analysis Appropriate; Person-time was calculated from the return date of the 
family history questionnaire (1991) to the date of prostate cancer 
diagnosis, death or April 30, 2003, whichever came first; age-
adjusted.  Rate ratios determined with Cox proportional hazard 
models; multivariate analysis for confounders.   
Internal Validity Fair  
External Validity Poor-Fair 
Overall Fair 
 
Rodriguez et al., 1997
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Design Prospective cohort within a cross-sectional survey 
Source Population 508,576 males in the Cancer prevention study (ACS) enrolled by 
volunteers in all 50 states in 1982; purpose of the Cancer Prevention 
Study II was to assess mortality related to cancer  
Inclusion Criteria Completion of questionnaire 
Exclusion Criteria Excluded for incomplete racial data (2,399), personal history of 
prostate cancer (3,303), other cancer (21,863) 
Study Population 481,011 men with no prior history enrolled by volunteers across all 
50 states, DC, Puerto Rico who agreed to participate and 
successfully completed the questionnaire.  Median age was 57, 75% 
between 47-70, none younger than 30. 
Risk Factors Consistent 
Between Groups  
Considerable differences seen in exercise between exposed and 
unexposed; however age was not described.  No difference with 
regard to race, religion, sibship, education, vasectomy, BMI, 
smoking history, vegetable consumption, fat consumption 
Attrition <5% at 9 years follow-up; follow-up equal in both groups 
Measurement of 
exposure 
Questionnaire given by volunteers; defined by 1) any reported 
family history of prostate cancer in father or brother, father only, 
brother only, by number of affected first-degree relatives, age of 
affected family member diagnosis (before and after age 65) 
Measurement of 
outcomes 
Blinding uncertain. Vital status and cause of death of study 
participants was determined using two approaches: volunteers 
making personal inquiries in 1984, 1986, 1988, automated linkage 
using the National Death Index used to complete follow-up through 
1991.  ICD-9 indicating prostate cancer as underlying cause. Nine 
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years may be inadequate to observe outcome 
Statistical Analysis Cox proportional hazards modeling to compute rate ratios; adjusted 
for potential risk factors, stratified by age, controlled for race; 
accounted for sibship size and age of diagnosis.   
Internal Validity Poor-Fair 
External Validity Fair 
Overall  Fair 
 
Thompson et al., 2006
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Study Design Nested case-control 
Source Population 18,882 men 55 or older with normal DRE and PSA less than 3 
randomly assigned to finasteride or placebo for 7 years
31
 
Inclusion Criteria 55 years old or older and had a normal DRE and a PSA level less 
than or 
equal to 3 ng/mL. 
Exclusion Criteria Clinically significant coexisting conditions, AUA symptom score 
over 20 
Study Population 5519 men from the placebo group who underwent biopsy, had at 
least one PSA measurement and DRE within the year before the 
biopsy and had at least two PSA measurements performed during the 
3 years before biopsy; 17% positive family history, 96% white, 91% 
with 5-7 PSA screens 
Risk Factors Consistent 
Between Groups  
Unable to determine distribution of age/baseline characteristics in 
cases or controls, or exposed versus non-exposed 
Attrition <5% 
Measurement of 
exposure 
Family history obtained by interview at time of biopsy 
Measurement of 
outcomes 
Gleason - central pathologist, no mention of blinding 
Internal Validity Grade Fair-Good 
External Validity Grade Poor-Fair 
Statistical Analysis Multivariate – adjusted appropriately; identified/addressed 
interaction terms 
Overall Fair 
 
Thompson et al., 2007
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Study Design Nested case-control 
Source Population 18,882 men 55 or older with normal DRE and PSA less than 3 
randomly assigned to finasteride or placebo for 7 years;
31
 
Inclusion Criteria All participants who underwent biopsy at any of seven annual visits, 
including end-of-study biopsy; AUA symptom score less than 20.   
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Exclusion Criteria  Clinically significant coexisting conditions, AUA symptom score 
over 20 
Study Population N=5,675 from 9459 randomized to finasteride arm who had at least 
one PSA measurement and DRE within the year before the biopsy 
and had at least two PSA measurements performed during the 3 
years before biopsy; 93% white; 83% had 7 or more PSA screens; 
86% had 7 or more DREs, 96% had been on finasteride for at least 5 
years.   
Risk Factors Consistent 
Between Groups  
Unable to determine distribution of age/baseline characteristics in 
cases or controls, or exposed versus non-exposed 
Attrition 22% - unable to determine from which group 
Measurement of 
exposure 
Family history obtained by interview  
Measurement of 
outcomes 
Biopsy with rising PSA or at end of study; notably, PSA threshold 
levels for biopsy were lowered to account for effect of finasteride 
(bias toward null); Gleason – central pathologist, no mention of 
blinding 
Internal Validity Grade Poor-fair 
External Validity Grade Poor 
Statistical Analysis Multivariate – adjusted for confounders 
Overall Poor 
 
Schuurman et al., 1999
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Study Design Nested Case-Control 
Source Population 58,279 men 55-69 from 204 municipalities in Finland (data from the 
Netherlands Cohort Study (assessing diet and cancer).
91
  The cohort 
included 58,279 men and 62,573 women ages 55-69 years at the 
start of the study. 
Inclusion Criteria Completion of baseline questionnaire 
Exclusion Criteria  Prevalent cancer at baseline other than skin cancer and subjects with 
incomplete or inconsistent dietary data according to criteria. 
Study Population Study Cases: 642 men with overall prostate cancer at 6.3 years 
(median follow-up) Study Controls: 1688 (random sample of the 
cohort – randomized selection process unclear) Cases of advanced 
prostate cancer: 213 Cases of local prostate cancer: 226 
Risk Factors Consistent 
Between Groups  
Unable to determine comparability of exposed/non-exposed, 
cases/controls 
Attrition High: TNM Stage available for only 35% 
Measurement of 
exposure 
Self-administered questionnaire at baseline 
Measurement of 
outcomes 
Cancer registries and/or TNM staging/clinical staging; Stage 
determination unclear; no blinding mentioned 
Internal Validity Poor-Fair 
External Validity Poor-Fair 
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Statistical Analysis Adjusted for age, age at diagnosis, race; subgroup analysis for 
advanced disease; power may not be adequate; case-cohort approach 
for analysis for calculation of cancer incidence rates, the number of 
cases for the entire cohort was used as the numerator, while person 
years at risk (denominator) were estimated using a random male 
sample of controls, the subcohort (N = 1688). 
Overall Poor 
 
Yen-Chen et al., 2008
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Study Design Retrospective Cohort 
Source Population 51,529 male health professionals (Health Professionals Follow-Up 
Study (HPFS) – dentists, optometrists, osteopaths, podiatrists, 
pharmacists, veterinarians aged 40-75 
Study Population Subcohort of the HPFS study; 42,144 participants provided data on 
family history; medical history; highly screened population with 8 
years follow-up (84% screened at least once in non-exposed, 92% in 
exposed); assessed with follow-up questionnaires, if permission 
granted authors searched hospital records and pathology reports 
Inclusion Criteria Completion of baseline questionnaire  
Exclusion Criteria Prior prostate cancer; excluded clinical stage T1a 
Comparison of groups 
(exposed, non-exposed; 
cases, controls) 
Age, race socioeconomic variables comparable between exposed and 
unexposed; exposed group had higher prior PSA-screening rates and  
Attrition 26%; Gleason available for 2,718 cases (74%); TNM Stage available 
for 2,603 (70.4%);  
Measurement of 
exposure 
Questionnaire; follow-up questionnaires, medical records; interview 
of family members 
Measurement of 
outcomes 
TNM Stage and Gleason through medical records and pathology 
review; risk of bias due to exclusion of T1a cancers (authors’ 
attempt to reduce overdiagnosis of indolent cancer);  approximately 
90% of the 3,695 cases using medical records and pathology reports; 
remaining 10% per family interview;  follow-up period may be 
inadequate to assess outcome; blinding unknown; 
Internal Validity  Fair 
External Validity Poor-Fair 
Statistical Analysis Stratification by age, covariates adjusted for included vigorous 
physical activity, cigarette smoking, tomato sauce, calcium, alpha-
linolenic acid, fish, red meat.  Did not report model adjusted for age, 
race.  Concern for adjustment of clinically insignificant risk factors.  
Overall  Fair 
 
Spangler et al., 2005
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Study Design Case-control 
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Source Population Men in the Pennsylvania aged 40 and over, diagnosed with prostate 
cancer 
Inclusion Criteria Prostate cancer (incident diagnosis) 
Exclusion Criteria Prior cancer diagnosis, at any site, except non-melanoma skin 
cancer, self-reported current use of finasteride, or were non-incident 
prostate cancer cases (diagnosed more than 12 months before study 
ascertainment. No date of diagnosis in EMR; no knowledge of 
family history 
Study Population All participating men diagnosed with prostate cancer at the UPHS 
(PENN) urologic oncology department clinics between 1995-2002; 
mean age 60.6; N=684 
Comparison of groups 
(exposed, non-exposed; 
cases, controls) 
Cases (Gleason):281, Controls: 272; Cases (T3a): 147, Controls: 446 
Cases(T3b): 37 Controls: 559; Cases (M1): 9 Controls: 653 
Cases defined as evidence of metastatic disease on MRI 
Unable to determine characteristics of cases versus controls (age, 
race) Selected from same population, but may not have same risk of 
overall and aggressive prostate cancer (risk of selection bias) 
Attrition High – approximately 50% for each outcome 
Measurement of 
exposure 
In-person interview; positive family history was first or second 
degree relative with prostate cancer 
Measurement of 
outcomes 
TNM staging (TNM did not include Nodal status and is thus less 
valuable.) Gleason - from surgical pathology reports. 
Internal Validity Poor-Fair 
External Validity Poor 
Statistical Analysis Odds-ratios  with logistic regression models – adjusted for 
confounders; power may be insufficient to assess certain outcomes 
Overall Poor 
 
Makinen et al., 2002
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Study Design Cross-sectional within cohort (screened arm of a randomized 
controlled trial) 
Source Population “Nested” cohort with ERSPC,
4
  approximately 80,000 men aged 55 
to 67 from the population register from 1996-1999; part of the 
ERSPC (the finish center);  
Inclusion Criteria Men who provided baseline information (age, family history etc.) 
Exclusion Criteria Prior diagnosis of prostate cancer 
Study Population 20,311  men randomized to the screening arm; 964 (4.7%) with FH; 
all men in this arm were referred for biopsy if PSA was 4 or over, 
1996-1999 – 3 years follow-up 
Comparison of groups 
(exposed, non-exposed; 
cases, controls) 
Unable to discern differences between exposed and non-exposed; 
median age of diagnosis is comparable however baseline/median age 
or range of age is not available 
Attrition <5% 
Measurement of Self-administered questionnaire (prior to screening); prevalence of 
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exposure family history <5% (approximates general US population) 
Measurement of 
outcomes 
Men with PSA over 4.0ng/mL received biopsy; TNM Stage, 
Gleason Score  
Internal Validity Poor-Fair 
External Validity Poor-Fair 
Statistical Analysis Stratified by family history, no mention of adjustments for 
confounders, no reference to covariates; Student T-Tests to compare 
age at diagnosis, Wilcox rank to determine relative risk of 
aggressive cancer 
Overall Poor 
 
Kotsis et al., 2002
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Study Design Case-control 
Source Population Middle aged men with access to health care and well-connected to 
specialists, volunteering to be referred. Men aged less than 56 years; 
Men in the Michigan University area and beyond are referred to 
University of Michigan for participation in the Prostate Cancer 
Genetics Project. 
Inclusion Criteria Recent diagnosis of prostate cancer at 55 or younger 
Exclusion Criteria Unknown family history, missing pre-diagnosis PSA, race other than 
white or black, pathology report of metastasis, enrollment following 
enrollment of blood relative 
Study Population Men less than 55 (median age 51, range 34-51) diagnosed with CaP 
and participated in study cohort between years 1995-1999.  Referred 
to University of Michigan for participation in the Prostate Cancer 
Genetics Project. Cases = 133, Controls = 126 same population, may 
not have same risk of developing outcome at baseline (risk of 
selection bias); screening status not specifically described, but likely 
high in both cases and controls; potentially higher in exposed than 
unexposed 
Comparison of groups 
(exposed, non-exposed; 
cases, controls) 
Unable to determine comparison of cases, study designed to 
determine association of family history and overall prostate cancer  
Attrition 10%; unable to determine distribution of attrition in cases and 
controls 
Measurement of 
exposure 
Questionnaire and confirmed by medical records; did not 
differentiate first-degree from 2
nd
 degree for predicting aggressive 
cancer 
Measurement of 
outcomes 
TNM Stage, Gleason 
Internal Validity Fair-Good 
External Validity Poor 
Statistical Analysis Adjustments for confounders; logistic regression for odds of Gleason 
less than 7 
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Overall Poor 
 
Valeri et al., 2000
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Study Design Case-control 
Source Population Men in France referred to urology departments for newly diagnosed 
prostate cancer or who had previously been known to have prostate 
cancer in the 1990s.    
Study Population 801 consecutive prostate cancer probands treated in three French 
urology departments between 1994-1997.   
Cases: Men with aggressive prostate cancer defined by TNM Stage 
III (T3N0M0) or IV (T4/xN0/xM0/x) or Gleason of 7 or more.   
Controls: men with not aggressive prostate cancer given above 
definitions.   
Inclusion Criteria Unable to determine detailed inclusion criteria 
Exclusion Criteria Unable or unwilling to provide family history 
Comparison of groups 
(exposed, non-exposed; 
cases, controls) 
Does not appear to be any appreciable difference between cases and 
controls with regard to exposure; otherwise unable to compare cases 
and controls.  Unable to determine prior screening or presence of 
symptoms in cases versus controls.  
Attrition 30%; multivariate analysis performed on 189/267  
Measurement of 
exposure 
In-person interview; sporadic 1 prostate cancer in relative,  
hereditary (one first ) with 2 or more after age 55; familial (two first-
degree), at least 1 after age 55 
Measurement of 
outcomes 
TNM Stage, Gleason Grade (no central review, no blinding 
mentioned) 
Statistical Analysis Multivariate analysis was performed on 189/267 comparing 
hereditary and sporadic (odds-ratio) 
Internal Validity Fair 
External Validity Poor  
Overall Poor 
 
Rohrmann et al., 2003
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Design Case-control 
Source Population Men in the Baltimore area diagnosed with prostate cancer who 
underwent radical prostatectomy between 1992 and 1999 
Study Population 498 of 1,544 consecutive men who underwent radical prostatectomy 
with a single surgeon who were under the age of 55 
Cases: men found to have Gleason score of 7 or more on review of 
surgical pathology or (T3a) extraprostatic extension 
Controls: men found to have Gleason of less than 7 or those without 
extraprostatic extension (T3a) 
Inclusion Criteria Age less than 55, cancer diagnosed and surgery performed in study 
time period.   
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Exclusion Criteria  Age 55 or more 
Risk Factors Consistent 
Between Groups  
Age is not comparable between exposed and not exposed in terms of 
age at surgery (P<0.01) but we do not have numerical representation 
of this difference.  We also do not know if age is comparable 
between cases and controls; mean pre-operative PSA is higher in 
men without family history. 
Attrition 27% did not return the questionnaire, unclear distribution between 
cases and controls  
Measurement of 
exposure 
Mailed questionnaire to all 498 men with follow-up telephone 
reminder; 
Measurement of 
outcomes 
Gleason and extraprostatic extension determined by surgical 
pathology 
Statistical Analysis Logistic regression to estimate odds ratio of high grade disease in 
men undergoing radical prostatectomy for prostate cancer who 
reported a positive family history; stratified race (though did not 
report) and for age at surgery as follows: less than 47, 47-49.9, 50-
51, 52-53.9, 54-54+.  Used age at surgery as surrogate for age at 
screening.  Tested for multiplicative interaction with cross-product 
(age-BMI).  Wald test for significance; age stratification and 
identification of interaction terms in logistic model.     
Internal Validity Grade Fair  
External Validity Grade Poor 
Overall Poor   
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# of records identified through database 
searching  
8,706 
 
MEDLINE
®
: 912 
Embase: 368 
 
# of additional records identified through 
expert consultation, web of science, hand 
search of 38 references: 128 
Total # of records after duplicates removed 
780 
# of records screened 
780 
# of records 
excluded 
742 
# of full-text articles assessed for 
eligibility 
38 
# of studies (articles) included in 
qualitative synthesis of systematic 
review  
11 
27 Excluded, with reasons: 
Wrong publication  
 type / study design 1 
Wrong setting  0 
Wrong Exposure 2 
Wrong Comparator 2 
Wrong Outcome 20 
Poor Quality 2 
 
 
 
 
# of studies included in narrative 
synthesis of systematic review  
11 
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Figure 2 – Flow diagram of search 
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APPENDIX 2 
Search strategy for PubMed:  
(medical history taking OR family history OR familial OR hereditary) AND risk factors 
AND (Prostatic Neoplasms OR prostate cancer) AND (prostate neoplasm/epidemiology 
OR Prostatic Neoplasms/genetics OR Prostatic Neoplasms/mortality OR Age Factors OR 
genetic predisposition to disease OR Tumor Markers, Biological/blood OR prostate-
specific antigen/blood OR predictive value of tests OR prostatic neoplasms/prevention & 
control OR medical history taking/statistics & numerical data OR risk assessment OR 
follow-up studies OR retrospective studies OR prospective studies OR Cohort studies OR 
retrospective cohort studies OR prospective cohort studies OR incidence OR father OR 
brother) 781 results 
Limits to the above search were applied and included humans, male, clinical trial, meta-
analysis, randomized-controlled trial, adults aged 19 years and over published between 
1992 and 2012. (96 studies).  Of note, the date of 1992 was selected because it coincided 
with widespread clinical acceptance and use of the prostate specific antigen level as a 
potential screening tool for prostate cancer.  The above search was adapted with the help 
of the research librarian for the Embase database. Studies were also identified through 
hand searches of reference lists from studies that met inclusion criteria, systematic reviews 
and meta-analyses obtained from the search in addition to expert recommendations* (Paul 
Godley, Ronald Chen).   
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